Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions

Identifieur interne : 002689 ( Main/Exploration ); précédent : 002688; suivant : 002690

Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions

Auteurs : Christopher G. Goetz [États-Unis] ; Joanne Wuu [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Charles H. Adler [États-Unis] ; Stanley Fahn [États-Unis] ; Curt R. Freed [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren C. Olanow [États-Unis] ; Ira Shoulson [États-Unis] ; P. K. Tandon [États-Unis] ; Sue Leurgans [États-Unis]

Source :

RBID : ISTEX:82643ADC619ABE1A6F2150AE9F9D4CBDD8F1CD7A

Descripteurs français

English descriptors

Abstract

Placebo‐associated improvements have been previously documented in small series of Parkinson's disease (PD) patients. Using a strict definition of placebo‐associated improvement, we examined rates and timing of placebo responses to identify patient‐ and study‐based characteristics, predicting positive placebo response in several PD clinical trials. We collected individual patient data from the placebo groups of 11 medical and surgical treatment trials involving PD patients with differing PD severities and placebo‐assignment likelihoods. We defined a positive placebo response as ≥50% improvement in total Unified Parkinson's Disease Rating Scale motor (UPDRSm) score or a decrease by ≥2 points on at least two UPDRSm items compared to baseline. We calculated positive placebo response rates at early (3–7 weeks), mid (8–18 weeks), and late (23–35 weeks) stages of follow‐up. Odds ratios for patient‐ and study‐based characteristics were obtained from a model fitted using generalized estimating equations. There were 858 patients on placebo who met inclusion criteria for analysis. Three studies involved patients without need of symptomatic treatment, two involved patients without motor fluctuations needing symptomatic treatment, and six (three medical and three surgical) involved patients with motor fluctuations. The overall placebo response rate was 16% (range: 0–55%). Patients with higher baseline UPDRSm scores and studies that focused on PD with motor fluctuations, surgical interventions, or those with a higher probability of placebo assignment showed increased odds of positive placebo response. Placebo responses were temporally distributed similarly during early, mid, and late phases of follow‐up. Placebo‐related improvements occur in most PD clinical trials and are similarly distributed across all 6 months of follow‐up. Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials. © 2008 Movement Disorder Society

Url:
DOI: 10.1002/mds.21894


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions</title>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</author>
<author>
<name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
</author>
<author>
<name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
</author>
<author>
<name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name>
</author>
<author>
<name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
</author>
<author>
<name sortKey="Freed, Curt R" sort="Freed, Curt R" uniqKey="Freed C" first="Curt R." last="Freed">Curt R. Freed</name>
</author>
<author>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author>
<name sortKey="Olanow, Warren C" sort="Olanow, Warren C" uniqKey="Olanow W" first="Warren C." last="Olanow">Warren C. Olanow</name>
</author>
<author>
<name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
</author>
<author>
<name sortKey="Tandon, P K" sort="Tandon, P K" uniqKey="Tandon P" first="P. K." last="Tandon">P. K. Tandon</name>
</author>
<author>
<name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:82643ADC619ABE1A6F2150AE9F9D4CBDD8F1CD7A</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.21894</idno>
<idno type="url">https://api.istex.fr/document/82643ADC619ABE1A6F2150AE9F9D4CBDD8F1CD7A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000131</idno>
<idno type="wicri:Area/Istex/Curation">000131</idno>
<idno type="wicri:Area/Istex/Checkpoint">001245</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Goetz C:placebo:response:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18228568</idno>
<idno type="wicri:Area/PubMed/Corpus">002322</idno>
<idno type="wicri:Area/PubMed/Curation">002322</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002140</idno>
<idno type="wicri:Area/Ncbi/Merge">002037</idno>
<idno type="wicri:Area/Ncbi/Curation">002037</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002037</idno>
<idno type="wicri:Area/Main/Merge">003267</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0247738</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001285</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001A34</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001136</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Goetz C:placebo:response:in</idno>
<idno type="wicri:Area/Main/Merge">003744</idno>
<idno type="wicri:Area/Main/Curation">002689</idno>
<idno type="wicri:Area/Main/Exploration">002689</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions</title>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Emory University, Atlanta, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</wicri:regionArea>
<placeName>
<region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation wicri:level="4">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Columbia University, New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
</author>
<author>
<name sortKey="Freed, Curt R" sort="Freed, Curt R" uniqKey="Freed C" first="Curt R." last="Freed">Curt R. Freed</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Colorado Medical Center, Denver, Colorado</wicri:regionArea>
<placeName>
<region type="state">Colorado</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName>
<region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author>
<name sortKey="Olanow, Warren C" sort="Olanow, Warren C" uniqKey="Olanow W" first="Warren C." last="Olanow">Warren C. Olanow</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Tandon, P K" sort="Tandon, P K" uniqKey="Tandon P" first="P. K." last="Tandon">P. K. Tandon</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global BioMedical Operations, Genzyme Corporation, Cambridge, Massachusetts</wicri:regionArea>
<placeName>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-04-15">2008-04-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="690">690</biblScope>
<biblScope unit="page" to="699">699</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">82643ADC619ABE1A6F2150AE9F9D4CBDD8F1CD7A</idno>
<idno type="DOI">10.1002/mds.21894</idno>
<idno type="ArticleID">MDS21894</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Clinical trial</term>
<term>Comparative study</term>
<term>Female</term>
<term>Fetal Tissue Transplantation</term>
<term>Humans</term>
<term>Male</term>
<term>Nervous system diseases</term>
<term>Odds Ratio</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (surgery)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Placebo</term>
<term>Placebo Effect</term>
<term>Placebos</term>
<term>Randomized Controlled Trials as Topic (statistics & numerical data)</term>
<term>Risk Factors</term>
<term>Surgery</term>
<term>Swine</term>
<term>placebo</term>
<term>randomized clinical trials</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Female</term>
<term>Fetal Tissue Transplantation</term>
<term>Humans</term>
<term>Male</term>
<term>Odds Ratio</term>
<term>Placebo Effect</term>
<term>Placebos</term>
<term>Risk Factors</term>
<term>Swine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Chirurgie</term>
<term>Essai clinique</term>
<term>Etude comparative</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Placebo</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Chirurgie</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Placebo‐associated improvements have been previously documented in small series of Parkinson's disease (PD) patients. Using a strict definition of placebo‐associated improvement, we examined rates and timing of placebo responses to identify patient‐ and study‐based characteristics, predicting positive placebo response in several PD clinical trials. We collected individual patient data from the placebo groups of 11 medical and surgical treatment trials involving PD patients with differing PD severities and placebo‐assignment likelihoods. We defined a positive placebo response as ≥50% improvement in total Unified Parkinson's Disease Rating Scale motor (UPDRSm) score or a decrease by ≥2 points on at least two UPDRSm items compared to baseline. We calculated positive placebo response rates at early (3–7 weeks), mid (8–18 weeks), and late (23–35 weeks) stages of follow‐up. Odds ratios for patient‐ and study‐based characteristics were obtained from a model fitted using generalized estimating equations. There were 858 patients on placebo who met inclusion criteria for analysis. Three studies involved patients without need of symptomatic treatment, two involved patients without motor fluctuations needing symptomatic treatment, and six (three medical and three surgical) involved patients with motor fluctuations. The overall placebo response rate was 16% (range: 0–55%). Patients with higher baseline UPDRSm scores and studies that focused on PD with motor fluctuations, surgical interventions, or those with a higher probability of placebo assignment showed increased odds of positive placebo response. Placebo responses were temporally distributed similarly during early, mid, and late phases of follow‐up. Placebo‐related improvements occur in most PD clinical trials and are similarly distributed across all 6 months of follow‐up. Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Arizona</li>
<li>Colorado</li>
<li>Floride</li>
<li>Géorgie (États-Unis)</li>
<li>Illinois</li>
<li>Massachusetts</li>
<li>État de New York</li>
</region>
<settlement>
<li>New York</li>
<li>Tampa</li>
</settlement>
<orgName>
<li>Université Columbia</li>
<li>Université de Floride du Sud</li>
</orgName>
</list>
<tree>
<country name="États-Unis">
<region name="Illinois">
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</region>
<name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name>
<name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<name sortKey="Freed, Curt R" sort="Freed, Curt R" uniqKey="Freed C" first="Curt R." last="Freed">Curt R. Freed</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
<name sortKey="Olanow, Warren C" sort="Olanow, Warren C" uniqKey="Olanow W" first="Warren C." last="Olanow">Warren C. Olanow</name>
<name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<name sortKey="Tandon, P K" sort="Tandon, P K" uniqKey="Tandon P" first="P. K." last="Tandon">P. K. Tandon</name>
<name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
<name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002689 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002689 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:82643ADC619ABE1A6F2150AE9F9D4CBDD8F1CD7A
   |texte=   Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024